New CLSI document addresses susceptibility testing for infrequently isolated or fastidious bacteria organisms not previously targeted in guidelines for microbiology labs
=========================================================================================================================================================================

Wayne, Pennsylvania --- May, 2006 --- Clinical and Laboratory Standard Institute (CLSI, formerly NCCLS) recently published a document, titled *Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline (M45-A)*, which provides guidance to clinical microbiology laboratories for standardized susceptibility testing of infrequently isolated or fastidious bacteria that are not presently included in CLSI\'s benchmark documents: *M2 -- Performance Standards for Antimicrobial Disk Susceptibility Tests, M7 -- Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically,* or *M11 --- Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria*.

Infections due to organisms addressed in M45 occur less frequently than many of the organisms presently covered in CLSI documents M2 and M7. The goal of this document is to propose test conditions and interpretive criteria based on a careful review of published microbiological data and clinical literature regarding therapy for these organisms. M45 is intended to assist clinical microbiology laboratories in determining an approach for testing these unusual organisms that is relevant to individual practice settings.

In addition, M45-A describes the traditional microdilution and agar disk diffusion methods and includes a series of procedures designed to standardize performance. The tabular information included represents the most currently available information for drug selection, interpretation, and quality control for infrequently isolated or fastidious bacterial pathogens. As more information becomes available, changes will be incorporated into future revisions of this document.

CLSI publishes new guideline for blood cultures
===============================================

Wayne, Pennsylvania --- November 2006 --- The prompt and accurate detection of bacteremia and fungemia is one of the most important functions of clinical microbiology laboratories. Guidelines for the collection, processing, and interpretation of blood cultures are needed so that laboratories and providers use optimal laboratory methods for recovering specific pathogens, interpret the results correctly, and help control healthcare costs.

This document provides recommendations for the collection, transport, and processing of blood cultures as well as guidance for the recovery of pathogens from blood specimens taken from patients who are suspected of having bacteremia or fungemia. Included in the guideline are recommendations for the (i) clinical importance of blood cultures; (ii) specimen collection and transportation; critical factors in the recovery of pathogens from blood specimens; (iii) special topics, including pediatric blood cultures, catheter-related bloodstream infections, infective endocarditis, patients receiving antimicrobial therapy, rare and fastidious pathogens, and test of cure; (iv) reporting results; (v) interpreting blood culture results; (vi) safety issues; and (vii) quality assurance.

This guideline is intended to provide guidance to clinical microbiologists and other laboratorians (e.g., pathologists, laboratory supervisors, laboratory managers) for the recovery of pathogens from blood specimens taken from patients who are suspected of having bacteremia or fungemia.

CLSI publishes new approved guideline for optimizing viral culture results
==========================================================================

Wayne, Pennsylvania, USA ---December 2006 --- The nature of the cell culture system is one that is inherently variable and thus remains susceptible to numerous adverse conditions that can lead to unreliable results. CLSI has recently published *Viral Culture; Approved Guideline (M41-A)*, which provides recommendations for optimizing culture results. This document provides guidance for viral culture and identification procedures that are typically performed in the clinical virology laboratory setting using commercially available reagents and monolayered cell cultures.

M41-A is designed to identify the many variables associated with viral culture procedures and to provide guidance regarding: specimen collection, processing, and inoculation; cell culture selection, assessment, maintenance, and quality control; isolate detection and identification; and reporting and interpretation of test results.

This document includes procedures and guidance that are appropriate for different laboratory settings, ranging from those offering a limited culture menu (e.g., herpes simplex virus \[HSV\]) to those performing more comprehensive viral culture. This document also includes cautionary notes related to recent safety concerns regarding BSL-3 and BSL-4 agents that have been identified as either potential biologic threats (e.g., variola) or emergent infections (e.g., severe acute respiratory syndrome-coronavirus \[SARS-CoV\], avian influenza).

CLSI publishes new antimicrobial susceptibility testing standard
================================================================

Wayne, Pennsylvania, USA --- January 2007 --- CLSI has recently published the annual update of the well-known antimicrobial susceptibility testing standard, *Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement (M100-S17)*, which provides updates of the latest recommendations for detecting emerging resistance of aerobic bacteria --- arranged in tabular format. The "breakpoints" included in the supplement are defined as specific values on the basis of which bacteria can be assigned to the clinical categories of susceptible, intermediate, or resistant. This essential information assists clinicians with drug selection, interpretation, and quality control using the procedures standardized in CLSI documents *Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard -- Ninth Edition (M2-A9)*; and *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard -- Seventh Edition (M7-A7)*.

This edition of the supplement includes updated tables from CLSI\'s disk (M2-A9) susceptibility and MIC (M7-A7) testing standards. In addition, the document provides three pages of adhesive index tabs, which can be inserted for quick access to each table.

Updates include (i) new disk diffusion and MIC interpretive criteria for colistin and polymyxin B; (ii) new antimicrobial agents and QC ranges; (iii) preparation of stock solutions for antimicrobial agents provided with activity expressed as units; (iv) added information on the development of resistance and testing of repeat isolates; (v) modified recommendations for testing and reporting designated clusters of agents with similar interpretive results and clinical efficacy; (vi) recommendations for reporting critical results; and (vii) suggestions for verification and confirmation of susceptibility testing results for Neisseria meningitidis.

CLSI publishes new antimicrobial susceptibility testing standard for anaerobic bacteria
=======================================================================================

Wayne, Pennsylvania, USA ---February 2007 --- CLSI has recently published an updated standard, *Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard -- Seventh Edition (M11-A7)*, which provides reference methods for the determination of minimal inhibitory concentrations (MICs) of anaerobic bacteria by agar dilution and broth microdilution. The document is complete with updated tables for antimicrobial susceptibility testing (AST) of anaerobic bacteria.

Susceptibility testing of anaerobes is recommended for surveillance purposes and for specific clinical situations. Two endpoint-determining susceptibility testing methods for anaerobic bacteria are described in the M11 standard. The agar dilution method (Wadsworth) remains the reference standard, and is well suited for surveillance testing and research. It is also the standard to which other methods are compared. Broth microdilution is well suited for the clinical laboratory, but is currently limited to testing of Bacteroides fragilis group organisms and selected antibiotics.

Key updates in the standard include (i) new QC and interpretive criteria for moxifloxacin; (ii) new QC strain *Clostridium difficile* with QC ranges for various antimicrobial agents; (iii) alternative methods for generating an anaerobic environment; and (iv) new antimicrobial agents and QC ranges to test for and report.

CLSI is a global, non-profit, membership-based organization dedicated to developing standards and guidelines for the healthcare and medical testing community. CLSI\'s unique consensus process facilitates the creation of standards and guidelines that are reliable, practical, and achievable for an effective quality system.

For additional information on CLSI or for further information regarding this release, visit our website at <http://www.clsi.org> or call +610.688.0100.
